Marcus F I
J Am Coll Cardiol. 1985 May;5(5 Suppl A):82A-90A. doi: 10.1016/s0735-1097(85)80466-6.
Drug interactions with digoxin are important because of this agent's narrow therapeutic index. Among the drugs that can decrease digoxin bioavailability are cholestyramine, antacid gels, kaolin-pectate, certain antimicrobial drugs and cancer chemotherapeutic agents. In selected patients, antibiotics may enhance digoxin bioavailability by eliminating intestinal flora that metabolize digoxin. Antiarrhythmic drugs, such as quinidine and amiodarone, can markedly increase steady state serum digoxin levels. Certain calcium channel blocking drugs, particularly verapamil, have a similar effect. Potassium-sparing diuretic drugs, such as spironolactone, can alter digoxin pharmacokinetics. Indomethacin may decrease renal excretion of digoxin in preterm infants. Finally, rifampin, an antibiotic used in the treatment of tuberculosis, may lower steady state serum digoxin levels in patients with severe renal disease. Physicians must maintain constant vigilance whenever medications are added to or withdrawn from a therapeutic regimen that includes digoxin.
由于地高辛的治疗指数较窄,所以药物与地高辛之间的相互作用很重要。可降低地高辛生物利用度的药物包括考来烯胺、抗酸凝胶、高岭土果胶、某些抗菌药物和癌症化疗药物。在特定患者中,抗生素可通过消除代谢地高辛的肠道菌群来提高地高辛的生物利用度。抗心律失常药物,如奎尼丁和胺碘酮,可显著提高地高辛的稳态血清水平。某些钙通道阻滞剂,特别是维拉帕米,也有类似作用。保钾利尿药,如螺内酯,可改变地高辛的药代动力学。吲哚美辛可能会降低早产儿地高辛的肾排泄。最后,用于治疗结核病的抗生素利福平,可能会降低重症肾病患者地高辛的稳态血清水平。每当在包含地高辛的治疗方案中添加或停用药物时,医生都必须持续保持警惕。